<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809870</url>
  </required_header>
  <id_info>
    <org_study_id>UKE Hamburg</org_study_id>
    <nct_id>NCT04809870</nct_id>
  </id_info>
  <brief_title>Esophagectomy in Patients With Liver Cirrhosis</brief_title>
  <official_title>Esophagectomy in Patients With Liver Cirrhosis - an Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective and confounder adjusted comparison of perioperative and longterm outcomes of&#xD;
      patients requiring an esophagectomy for esophageal cancer with and without concomitant liver&#xD;
      cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">April 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 18, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major complication</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Clavin Dindo ≥ 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anastomotic leakage rate</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Rate of endoscopically diagnosed anastomotic leakage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis rate</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Rate of participants with ≥ 2 points in Sepsis-related organ failure (SOFA) score within hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure rate</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Rate of acute kidney insufficiency (AKI) II-III (AKI Kidney Disease: Improving Global Outcomes (KDIGO) Guidelines)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic failure rate</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Number of participants with clinical diagnosis: coagulopathy, icterus and potentially hepatic encephalopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac complication</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>cardiac complication requiring pharmacological treatment or intervention and / or ICU surveillance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chylus fistula rate</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Concentration of triglycerides (TG) in drain fluids ≥ 3 times TGs i.s.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary complications</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Pneumonia requiring antibiotics, ventilatory insufficiency requiring supportive therapy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">170</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>LC (liver cirrhotic patients)</arm_group_label>
    <description>Patients with concomitant liver cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-LC (non liver cirrhotic patients)</arm_group_label>
    <description>Patients without concomitant liver cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis</description>
    <arm_group_label>LC (liver cirrhotic patients)</arm_group_label>
    <arm_group_label>Non-LC (non liver cirrhotic patients)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        retrospective analysis of a prospective maintained database of EC patients operated at the&#xD;
        institution between 2012 to 2016&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  primary esophageal cancer with indication for curative treatment&#xD;
&#xD;
          -  follow up period ≥ 5 years&#xD;
&#xD;
          -  LC cohort: pre- or intraoperative histological proof of liver cirrhosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  recurrent esophageal cancer&#xD;
&#xD;
          -  missing indication for curative treatment of esophageal cancer&#xD;
&#xD;
          -  esophagectomy for benign esophageal lesions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Hamburg Medical Institutions</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophagectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

